Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Cadonilimab · AK-104

Bispecific antibody · Antagonist of programmed cell death protein 1 (PDCD1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) · developed by Akeso

Early Phase 1 Most advanced trial
1 Registered trials

What is Cadonilimab?

Cadonilimab is a bispecific antibody that binds to both PD-1 and CTLA-4 checkpoint receptors on tumor-infiltrating T lymphocytes. By blocking these inhibitory signals, it restores T-cell activation and proliferation, enhancing cytotoxic immune responses against tumor cells. It is being studied in resectable hepatocellular carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AK-104
Drug type
Bispecific antibody
Targets
programmed cell death protein 1 (PDCD1), cytotoxic T-lymphocyte-associated antigen 4 (CTLA4)
Mechanism
Antagonist of programmed cell death protein 1 (PDCD1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4)
Pathways
T-cell activation, T-cell proliferation, immune checkpoint inhibition
Therapy area
Oncology
Developer
Akeso
In trials of
MAIA
FDA status
Investigational, not approved in the US. Most advanced trial: Early Phase 1
UNII
6FYG1DS4NW

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07446257 Early Phase 1 Resectable Hepatocellular Carcinoma Recruiting MAIA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Resectable Hepatocellular Carcinoma

Other drugs acting on PDCD1 / CTLA4

Berahyaluronidase Alfa and Pembrolizumab FDA approved Ipilimumab FDA approved Nivolumab FDA approved Pembrolizumab FDA approved Toripalimab FDA approved Tremelimumab FDA approved Atigotatug/Nivolumab Phase 1 Balstilimab Phase 2/3 Botensilimab Phase 2/3 BPT567 Phase 1 Budigalimab Phase 2/3 CDX-585 Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.